Tryptophan metabolism pathway

The **tryptophan metabolism pathway** is a complex network of biochemical reactions responsible for breaking down the essential amino acid tryptophan into various metabolites. This process occurs in both host cells and microbiota and is crucial for synthesizing neurotransmitters such as serotonin and melatonin, as well as producing kynurenines and indoles[1][5]. The two main branches of this metabolic route are: 1. **Kynurenine Pathway:** The primary route for tryptophan catabolism (>95% of dietary tryptophan), leading to production of kynurenic acid, quinolinic acid, and ultimately nicotinamide adenine dinucleotide (NAD+). Key enzymes include indoleamine 2,3-dioxygenase (IDO1/IDO2) and tryptophan 2,3-dioxygenase (TDO)[3][5][6]. This branch plays significant roles in immune regulation—especially immunosuppression during inflammation—and has been implicated in cancer progression, neurodegeneration, cardiovascular diseases, aging-related disorders (“inflammaging”), and psychiatric conditions[3][4][6]. 2. **Serotonin Pathway:** A smaller fraction of tryptophan is converted into serotonin via hydroxylation by tryptophan hydroxylase followed by decarboxylation. Serotonin regulates mood, sleep-wake cycles, gut motility, among other physiological functions[5]. Other minor pathways involve conversion to indole derivatives by gut bacteria. **Therapeutic Target Status:** The “tryptophan metabolism pathway” itself is not a single molecular target but rather an umbrella term encompassing multiple enzymes that can be targeted individually—such as IDO1 or TDO—in therapeutic strategies against cancer or autoimmune diseases[4][6]. Thus it should not be considered a canonical drug target; instead its components are targets. **Disease Roles & Biomarkers:** Dysregulation leads to altered levels of metabolites like kynurenines or serotonin which serve as biomarkers for inflammation status or disease progression; e.g., elevated kynurenine/tryptophan ratio indicates increased IDO activity during chronic inflammation or malignancy[3]. **Safety Concerns & Drugs:** There are no drugs that interact with the entire “pathway”; interventions focus on inhibiting key enzymes like IDO1/TDO using small molecules under investigation for cancer immunotherapy. Safety concerns relate to off-target effects on immune tolerance and neurotransmitter balance when modulating these pathways. **Summary Note on Correctness:** Referring to “tryptophan metabolism pathway” as a single molecular drug target is incorrect—it describes an interconnected set of enzymatic processes rather than one discrete protein/receptor/enzyme suitable for direct pharmacological targeting. For structured data purposes it should be flagged as too broad/not a canonical molecular entity suitable for standardization per your conventions.[4]

Other names

Tryptophan metabolic pathwayTrp metabolismKynurenine pathway (for a major branch)Serotonin pathway (for another branch)